XOMA Corporation (NASDAQ:XOMA) CFO Thomas M. Burns sold 6,983 shares of XOMA Corporation stock in a transaction on Monday, November 13th. The shares were sold at an average price of $30.99, for a total transaction of $216,403.17. Following the completion of the sale, the chief financial officer now directly owns 13,538 shares of the company’s stock, valued at approximately $419,542.62. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
XOMA Corporation (XOMA) traded down $3.50 during mid-day trading on Wednesday, hitting $27.00. 321,100 shares of the company traded hands, compared to its average volume of 146,850. The company has a debt-to-equity ratio of 3.53, a current ratio of 3.45 and a quick ratio of 3.45. XOMA Corporation has a 1-year low of $3.96 and a 1-year high of $33.00.
Several research firms recently issued reports on XOMA. HC Wainwright set a $38.00 price objective on shares of XOMA Corporation and gave the company a “buy” rating in a research note on Tuesday. Zacks Investment Research raised shares of XOMA Corporation from a “hold” rating to a “strong-buy” rating and set a $33.00 price objective for the company in a research note on Friday, November 10th. Finally, Wedbush raised shares of XOMA Corporation from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $9.00 to $19.00 in a research note on Tuesday, September 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $30.00.
About XOMA Corporation
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with MarketBeat.com's FREE daily email newsletter.